StockNews.AI
UNCY
StockNews.AI
6 hrs

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

1. Unicycive CEO will attend two investor events in September 2025. 2. Lead treatment oxylanthanum carbonate is under FDA review for kidney disease. 3. UNI-494 has orphan drug designation for kidney transplant-related conditions. 4. Investor events may increase visibility and interest in UNCY. 5. Company focuses on novel therapies for chronic kidney disease.

4m saved
Insight
Article

FAQ

Why Bullish?

Investor events create opportunities for engagement and potential stock price increase, similar to previous occurrences in biotech stocks where visibility led to gains.

How important is it?

The article highlights critical investor engagement opportunities and ongoing FDA reviews, which are essential for stock performance and investor confidence.

Why Short Term?

Upcoming events in September 2025 can drive immediate investor interest and trading activity, closely following similar cases in biotech sectors during key events.

Related Companies

CKPTCRNXAMTI
August 26, 2025 07:00 ET  | Source: Unicycive Therapeutics, Inc. LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September. Event: H.C. Wainwright 27th Annual Global Investment Conference Type: Fireside chatDate/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET Event: Truist Securities Virtual Fireside ChatDate/Time: Wednesday, September 17, 2025, at 10 a.m. ET A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your conference representative. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X. Investor Contact: Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com Media Contact:Rachel VisiReal Chemistryredery@realchemistry.com SOURCE: Unicycive Therapeutics, Inc.

Related News